Annals of internal medicine · 2026
Projected Effect of 2026 Federal Changes to the Childhood Immunization Schedule on Chronic Hepatitis B Virus Infections in the United States.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohareb Amir M, Ganapathi Lakshmi, Dugdale Caitlin M, Rajbhandari Ruma, Ciaranello Andrea, Neilan Anne M, Jhaveri Ravi, Kim Arthur Y, Hyle Emily P
Аннотация
BACKGROUND: The United States recently proposed changes to the recommendations for childhood hepatitis B virus (HBV) vaccination.
OBJECTIVE: To project the effect of vaccine policy changes, if fully implemented, on chronic HBV infections.
DESIGN: Markov cohort state transition model of perinatal and childhood HBV infection.
DATA SOURCES: Published data on maternal HBV prevalence (0.4%) and hepatitis B surface antigen testing (99.5% sensitivity), childhood vaccine completion (universal birth-dose strategy: 91.1%; deferred strategy: 87.1%; shared decision-making strategy: 50.0%), and age-stratified risk for chronic HBV infection.
TARGET POPULATION: One-year birth cohort of U.S.-born infants (n = 3.6 million).
TIME HORIZON: 20 years.
INTERVENTION: Universal birth-dose vaccination, deferred (2-month) vaccination, and vaccination through shared decision making.
OUTCOME MEASURES: Numbers with chronic HBV infection and susceptibility to HBV, with 95% uncertainty intervals (UIs) derived from probabilistic sensitivity analysis.
RESULTS OF BASE-CASE ANALYSIS: Compared with the universal birth-dose strategy (255 childhood infections [95% UI, 130 to 530]), the deferred and shared decision-making strategies would increase chronic HBV infections in the 2026 birth cohort by 19% to 303 (95% UI, 155 to 610) and by 83% to 467 (95% UI, 209 to 1032), respectively. These strategies would also increase the number of HBV-susceptible people at year 20 (474 000 and 1 806 000) compared with the universal birth-dose strategy (232 000).
RESULTS OF SENSITIVITY ANALYSIS: In a scenario with lower vaccine coverage (84.5%) and higher HBV prevalence (maternal prevalence of 0.72% and higher risk for horizontal infection), chronic HBV infections would increase to 1700 and 2192, respectively, with the deferred and shared decision-making strategies.
LIMITATION: Uncertainty in horizontal HBV infection risk.
CONCLUSION: Proposed policy changes for vaccination through shared decision making are projected to result in an 83% increase in childhood HBV infections, and between 50% and 70% of children entering adulthood annually would be susceptible to HBV infection. Policymakers should reimplement recommendations for universal birth-dose vaccination.
PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
OBJECTIVE: To project the effect of vaccine policy changes, if fully implemented, on chronic HBV infections.
DESIGN: Markov cohort state transition model of perinatal and childhood HBV infection.
DATA SOURCES: Published data on maternal HBV prevalence (0.4%) and hepatitis B surface antigen testing (99.5% sensitivity), childhood vaccine completion (universal birth-dose strategy: 91.1%; deferred strategy: 87.1%; shared decision-making strategy: 50.0%), and age-stratified risk for chronic HBV infection.
TARGET POPULATION: One-year birth cohort of U.S.-born infants (n = 3.6 million).
TIME HORIZON: 20 years.
INTERVENTION: Universal birth-dose vaccination, deferred (2-month) vaccination, and vaccination through shared decision making.
OUTCOME MEASURES: Numbers with chronic HBV infection and susceptibility to HBV, with 95% uncertainty intervals (UIs) derived from probabilistic sensitivity analysis.
RESULTS OF BASE-CASE ANALYSIS: Compared with the universal birth-dose strategy (255 childhood infections [95% UI, 130 to 530]), the deferred and shared decision-making strategies would increase chronic HBV infections in the 2026 birth cohort by 19% to 303 (95% UI, 155 to 610) and by 83% to 467 (95% UI, 209 to 1032), respectively. These strategies would also increase the number of HBV-susceptible people at year 20 (474 000 and 1 806 000) compared with the universal birth-dose strategy (232 000).
RESULTS OF SENSITIVITY ANALYSIS: In a scenario with lower vaccine coverage (84.5%) and higher HBV prevalence (maternal prevalence of 0.72% and higher risk for horizontal infection), chronic HBV infections would increase to 1700 and 2192, respectively, with the deferred and shared decision-making strategies.
LIMITATION: Uncertainty in horizontal HBV infection risk.
CONCLUSION: Proposed policy changes for vaccination through shared decision making are projected to result in an 83% increase in childhood HBV infections, and between 50% and 70% of children entering adulthood annually would be susceptible to HBV infection. Policymakers should reimplement recommendations for universal birth-dose vaccination.
PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.